Australia’s largest private health insurer commits $10M to fund MDMA therapy for PTSD in first-of-its-kind program

MDMA-assisted therapy for PTSD gets a major new funding pathway in Australia as Medibank launches a first-of-its-kind program. Medibank commits AUD $10 million (about USD $6.5 million) to support patient access to MDMA therapy, alongside a long-term outcomes and health economics study led by researchers at the Australian National University (ANU). The pilot is delivered in partnership with psychedelic care provider Emyria, and it is positioned within a broader AUD $50 million mental health cash injection aimed at improving care models nationwide. The program also reflects ongoing access bottlenecks created by the regulatory pathway for MDMA, with payor coverage identified as a key factor determining who can realistically access psychedelic-assisted psychotherapy.